Showing results (131-140 of 158) with videos related to

Sort By:
Pageof 16
The Journal of Urology|February 9, 2026
Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort StudyTarek Lawen, Rebekka S Garcia, Matthew T Smith, et al.
Biomedical and Environmental Sciences : BES|September 27, 2014
Environmental and psycho-social factors related to prostate cancer risk in the Chinese population: a case-control studyMei Ling Li, Ji Lin, Jian Guo Hou, et al.
International Journal of Cancer|December 27, 2017
Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer modelsYong Luo, Abul Kalam Azad, Styliani Karanika, et al.
Molecular Cancer Research : MCR|September 10, 2009
Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progressionMasami Watanabe, Guang Yang, Guangwen Cao, et al.
BJU International|July 16, 2017
Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancerSpyridon P Basourakos, John W Davis, Brian F Chapin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated AktGustavo Ayala, Jun Yan, Rile Li, et al.
European Urology|December 6, 2020
Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional TherapiesWeranja Ranasinghe, Daniel D Shapiro, Hyunsoo Hwang, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2004
Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patientsTakefumi Satoh, Bin S Teh, Terry L Timme, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2011
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomyGuru Sonpavde, Timothy C Thompson, Rajul K Jain, et al.
The Lancet. Oncology|September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trialPaul G Corn, Elisabeth I Heath, Amado Zurita, et al.
Pageof 16